These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

451 related articles for article (PubMed ID: 16825867)

  • 41. Desensitization for drug allergy.
    Castells M
    Curr Opin Allergy Clin Immunol; 2006 Dec; 6(6):476-81. PubMed ID: 17088655
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hypersensitivity reactions to therapeutic monoclonal antibodies: Phenotypes and endotypes.
    Isabwe GAC; Garcia Neuer M; de Las Vecillas Sanchez L; Lynch DM; Marquis K; Castells M
    J Allergy Clin Immunol; 2018 Jul; 142(1):159-170.e2. PubMed ID: 29518427
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Anaphylaxis to chemotherapy and monoclonal antibodies.
    Castells MC
    Immunol Allergy Clin North Am; 2015 May; 35(2):335-48. PubMed ID: 25841555
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Nonallergic drug hypersensitivity reactions.
    Farnam K; Chang C; Teuber S; Gershwin ME
    Int Arch Allergy Immunol; 2012; 159(4):327-45. PubMed ID: 22832422
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Drug Desensitizations for Chemotherapy: Safety and Efficacy in Preventing Anaphylaxis.
    Caiado J; Castells MC
    Curr Allergy Asthma Rep; 2021 Jul; 21(6):37. PubMed ID: 34232411
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Desensitization for Drug Hypersensitivity to Chemotherapy and Monoclonal Antibodies.
    Bonamichi-Santos R; Castells M
    Curr Pharm Des; 2016; 22(45):6870-6880. PubMed ID: 27784245
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Successful desensitization to docetaxel after severe hypersensitivity reactions in two patients.
    Reeves DJ; Callahan MJ; Sutton GP
    Am J Health Syst Pharm; 2012 Mar; 69(6):499-503. PubMed ID: 22382481
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Management of hypersensitivity reactions to Carboplatin and Paclitaxel in an outpatient oncology infusion center: a 5-year review.
    Banerji A; Lax T; Guyer A; Hurwitz S; Camargo CA; Long AA
    J Allergy Clin Immunol Pract; 2014; 2(4):428-33. PubMed ID: 25017531
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A new non-dilution rapid desensitization protocol successfully applied to all-grade platinum hypersensitivity.
    Chung SJ; Kang SY; Kang RY; Kim YC; Lee KH; Kim TY; Han SW; Kang HR
    Cancer Chemother Pharmacol; 2018 Nov; 82(5):777-785. PubMed ID: 30105458
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Managing premedications and the risk for reactions to infusional monoclonal antibody therapy.
    Chung CH
    Oncologist; 2008 Jun; 13(6):725-32. PubMed ID: 18586928
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clopidogrel desensitization: case report and review of published protocols.
    Owen P; Garner J; Hergott L; Page RL
    Pharmacotherapy; 2008 Feb; 28(2):259-70. PubMed ID: 18225971
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Drug Hypersensitivity and Desensitizations.
    Castells MC
    Immunol Allergy Clin North Am; 2017 Nov; 37(4):xvii-xviii. PubMed ID: 28965644
    [No Abstract]   [Full Text] [Related]  

  • 53. Desensitization with oxaliplatin in patients intolerant of carboplatin desensitization.
    Rose PG; Metz C; Link N
    Int J Gynecol Cancer; 2014 Nov; 24(9):1603-6. PubMed ID: 25304679
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Use of a protocol to minimize hypersensitivity reactions with asparaginase administration.
    Bryant R
    J Intraven Nurs; 2001; 24(3):169-73. PubMed ID: 11530362
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clopidogrel desensitization protocol for the treatment of thienopyridine hypersensitivity.
    Walker NE; Fasano MB; Hobbs RA; Horwitz PA
    Crit Pathw Cardiol; 2007 Mar; 6(1):26-9. PubMed ID: 17667884
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Biphasic and delayed hypersensitivity reactions.
    Viale PH; Yamamoto DS
    Clin J Oncol Nurs; 2010 Jun; 14(3):347-56. PubMed ID: 20529796
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Outpatient desensitization of patients with moderate (high-risk) to severe platinum hypersensitivity reactions.
    Vetter MH; Khan A; Backes FJ; Bixel K; Cohn DE; Copeland LJ; Fowler JM; Salani R; Li Q; O'Malley DM
    Gynecol Oncol; 2019 Feb; 152(2):316-321. PubMed ID: 30503265
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Hypersensitivity reactions to oxaliplatin: cross-reactivity to carboplatin and the introduction of a desensitization schedule.
    Meyer L; Zuberbier T; Worm M; Oettle H; Riess H
    J Clin Oncol; 2002 Feb; 20(4):1146-7. PubMed ID: 11844841
    [No Abstract]   [Full Text] [Related]  

  • 59. Simplified Graded Infusion Strategy for Mitigation of Oxaliplatin Hypersensitivity.
    Alonso Martinez S; Segal NH; Cercek A; Yaeger R; Stadler Z; Kemeny NE; Nusrat M; Shahrokni A; Connell L; Saltz LB
    Clin Colorectal Cancer; 2022 Jun; 21(2):149-153. PubMed ID: 35125319
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Current Knowledge and Management of Hypersensitivity Reactions to Monoclonal Antibodies.
    Picard M; Galvão VR
    J Allergy Clin Immunol Pract; 2017; 5(3):600-609. PubMed ID: 28110056
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.